ARTICLE | Clinical News
CLTX to start Generx Phase II/III
January 10, 2001 8:00 AM UTC
Collateral Therapeutics said partner Schering filed an IND for a U.S. Phase IIb/III trial of CLTX's Generx Ad5FGF4 angiogenic FGF gene therapy product to treat coronary artery disease in patients with...